TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04202289

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nile Tilapia Fish Skin
Description: In the search of new therapies for burns, the skin of Brazil's most cultivated fish, the Nile tilapia, which was mostly a waste product (although sometimes used as a resistant material for artisanal handicraft), was suggested as a possibility for the development of a low-cost xenograft. Apart from non-infectious microbiota, Nile Tilapia Fish Skin presented histomorphological similarities with human skin in pre-clinical studies. It was shown to have a deep dermis formed by thick collagen fibers organized on parallel/horizontal and transversal/vertical arrangement and composed, in comparison, by larger amounts of type I collagen. Nile Tilapia Fish Skin did not present variations in its microscopic structure and tensile strength after glycerolization, irradiation and posterior rehydration, recovering its natural consistency after glycerol removal.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Silver Sulfadiazine Cream 1%
Description: Topical antibiotic commonly used for the treatment of superficial and deep partial-thickness burns.
Study: NCT00181649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human prolactin
Study: NCT03140956

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levodopa, carbidopa, ODM-104
Description: Crossover design. Study treatments will be administered in randomized order 4 times a day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levodopa, carbidopa, ODM-104
Description: Crossover design. Study treatments will be administered in randomized order 4 times a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa, carbidopa, ODM-104
Description: Crossover design. Study treatments will be administered in randomized order 4 times a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa, carbidopa, ODM-104
Description: Crossover design. Study treatments will be administered in randomized order 4 times a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa, carbidopa, ODM-104
Description: Crossover design. Study treatments will be administered in randomized order 4 times a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa, carbidopa, ODM-104
Description: Crossover design. Study treatments will be administered in randomized order 4 times a day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levodopa, carbidopa, ODM-104
Description: Crossover design. Study treatments will be administered in randomized order 4 times a day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levodopa, carbidopa, ODM-104
Description: Crossover design. Study treatments will be administered in randomized order 4 times a day.
Study: NCT04733716

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Using Tourniquet
Description: The purpose of this prospective randomized double blinded study was to compare the effect of using a tourniquet on early-stage pain and 1-year postoperative functional outcomes when patients were divided into two groups according to the pain threshold.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Using Tourniquet
Description: The purpose of this prospective randomized double blinded study was to compare the effect of using a tourniquet on early-stage pain and 1-year postoperative functional outcomes when patients were divided into two groups according to the pain threshold.
Study: NCT01057797

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise-specific self-efficacy
Description: Subjects in the experimental group will participate in a self-efficacy enhancing intervention designed to maximize (a) exercise-specific SE-UB strength training (b) self-efficacy for overcoming barriers to exercise and (c) SE-UB physical activities. The intervention incorporates strategies to maximize the primary sources of efficacy information: (a) mastery accomplishments, (b) social modeling, (c) social persuasion, (d) interpretation of physiological and affective symptoms.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Gentle chair exercise
Description: Gentle armchair fitness exercises will be used as a sham treatment to control for the attention that subjects receive in the two strength training groups. The armchair fitness exercises will be conducted in small groups (n=8-10 per group). Armchair exercises will include stretching of all major joints with an emphasis on the arms and shoulders, massage of muscles that can be reached from the armchair (scalp, neck, shoulders, lower back, abdomen and thighs) and imagery to promote relaxation. Each session will include: 5 minutes of slow stretching, 20 minutes of faster paced exercises, 5 minutes of slower paced stretches, followed by 5-10 minutes of massage and imagery for relaxation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: upper body strength training
Description: 16 weeks of lab-based upper body strength training using 8: modified lateral pull down, shoulder shrug, upright row, overhead pull down, front raise, front pull down, triceps extension, biceps curl. Training load and volume will be increased progressing from 70% to 80% of the maximum strength training and from 2 sets of 8-10 repetitions progressing to 3 sets. Each week subjects will train twice in the lab and once at home. Home exercises will include 1 set of 15-20 repetitions: biceps curl, triceps extension, front raises, lateral raises, overhead press, chest press and one-arm dumbbell row.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: upper body strength training
Description: 16 weeks of lab-based upper body strength training using 8: modified lateral pull down, shoulder shrug, upright row, overhead pull down, front raise, front pull down, triceps extension, biceps curl. Training load and volume will be increased progressing from 70% to 80% of the maximum strength training and from 2 sets of 8-10 repetitions progressing to 3 sets. Each week subjects will train twice in the lab and once at home. Home exercises will include 1 set of 15-20 repetitions: biceps curl, triceps extension, front raises, lateral raises, overhead press, chest press and one-arm dumbbell row.
Study: NCT03197194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alteplase
Description: alteplase administered as an intravenous infusion (0.9 mg/kg; maximum dose 90 mg): 10% given as an IV bolus, followed immediately by the remaining given as an IV infusion over 1 hour.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetylsalicylic acid
Description: one tablet of aspirin 300 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: One placebo oral tablet which doesn't contain the active ingredient acetyl salicylic acid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo IV
Description: IV saline solution (0.9 %):10 mL in a syringe administered over 1 minute, followed by 50 mL as an infusion over 1 hour
Study: NCT02086409

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Yogurt supplemented with vitamin D and calcium
Description: The product is a yogurt containing 200 IU of vitamin D and 400 mg of calcium. Participants take 2 yogurts per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Yogurt not supplemented with vitamin D and calcium
Description: The comparator is represented by a yogurt not supplemented with vitamin D and calcium.Participants take 2 yogurts per day.
Study: NCT01160094

Intervention type: DRUG
Intervention: Treatment
Description: patients treated with Lapatinib-Capecitabine after Trastuzumab Progression
Study: NCT01848509

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: With teletransmission
Description: Teletransmission of alerts
Study: NCT01126008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCRT with weekly docetaxel & cisplatin
Description: radiotherapy: 70Gy/35 fraction for 7 weeks chemotherapy: docetaxel 20mg/m2 and cisplatin 20mg/m2 weekly for 6 weeks
Study: NCT03114657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crenezumab
Description: Crenezumab was administered by intravenous (IV) infusion at 60mg/kg as per the dosing schedule described above.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was administered by intravenous (IV) infusion at 60mg/kg as per the dosing schedule described above.
Study: NCT00673426

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Enoxaparin sodic
Study: NCT02698644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoamyl-2-cyanoacrylate
Description: Isoamyl-2-cyanoacrylate will be injected inside fallopian tube hysteroscopically through ureteric catheter
Study: NCT02598011

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Toca 511
Description: Toca 511 consists of a purified retroviral replicating vector encoding a modified yeast cytosine deaminase (CD) gene. The CD gene converts the antifungal 5-flurocytosine (5FC) to the anticancer drug 5-FU in cells that have been infected by the Toca 511 vector

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Toca 511
Description: Toca 511 consists of a purified retroviral replicating vector encoding a modified yeast cytosine deaminase (CD) gene. The CD gene converts the antifungal 5-flurocytosine (5FC) to the anticancer drug 5-FU in cells that have been infected by the Toca 511 vector

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toca FC
Description: Toca FC is an extended-release formulation of flucytosine. Toca FC is supplied as 500 mg white, oblong tablets with TOCA FC embossed on one side and 500 embossed on the other side

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toca FC
Description: Toca FC is an extended-release formulation of flucytosine. Toca FC is supplied as 500 mg white, oblong tablets with TOCA FC embossed on one side and 500 embossed on the other side
Study: NCT02979080

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eisensulfat LOMAPHARM 50 mg
Description: Eisensulfat LOMAPHARM 50 mg administration for 120 days
Study: NCT03790605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 % curcumin chip
Description: CURCUMIN CHIP: 4x5x0.5mm chip of 1% curcumin in biodegradable hydroxy propyl methyl cellulose vehicle

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo chip
Description: PLACEBO CHIP: 4x5x0.5mm chip (identical to test chip except for the active therapeutic ingredient) in biodegradable hydroxy propyl methyl cellulose vehicle

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling and root planing
Description: Routine full mouth scaling and root planing within 48 hours will be performed at baseline prior to local placement of the chips

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Scaling and root planing
Description: Routine full mouth scaling and root planing within 48 hours will be performed at baseline prior to local placement of the chips
Study: NCT05416645

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: patients with GERD after LSG
Description: patients with GERD after LSG
Study: NCT01359618

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moxifloxacin placebo comparator
Description: Single dose, oral encapsulated tablet

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Moxifloxacin placebo comparator
Description: Single dose, oral encapsulated tablet
Study: NCT01729728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol
Description: Tapentadol oral solution single dose (1mg/kg body weight)
Study: NCT02397486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin E

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation therapy
Study: NCT02525536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trebananib 3 mg/kg
Description: Trebananib (AMG 386) 3 mg/kg, intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trebananib 10 mg/kg
Description: Trebananib (AMG 386) 10 mg/kg, intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trebananib 30 mg/kg
Description: Trebananib (AMG 386) 30 mg/kg, intravenous infusion.
Study: NCT00985426

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HEPLISAV-B
Description: Intramuscular (IM) injections of HEPLISAV-B at Weeks 0, 4, and 24

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix-B
Description: Intramuscular (IM) injections at Weeks 0, 4, 8, and 24

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo(saline) intramuscular (IM) injection at Week 8
Study: NCT05191589

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Haptic
Description: Trainees are randomized in this group to use the haptic device.
Study: NCT01330056

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FOPS
Description: * Functional organ preservation (FOPS) as a first-line treatment modality~* Postoperative RT or CRT may be included for the patients of this group.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: CRT
Description: * Concurrent chemoradiotherapy as a first-line treatment modality~* Salvage surgery may be applied for the patients with persistent or recurrent cancers after RT or CRT
Study: NCT02237560

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cybercycle-Game
Description: Exercising on a virtual-reality enhanced stationary recumbent bicycle while playing interactive 3D video-game for 6 months, 3-5x/week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cybercyle-Tour
Description: Exercising on virtual-reality enhanced stationary recumbent bicycle and pedaling through interactive 3D scenic bike tours for 6 months, 3-5x/week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Game Only
Description: While seated on a stationary recumbent seat play interactive 3D video-game for 6 months, 3-5x/week (no pedaling).
Study: NCT01743118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPS4251 Ointment
Description: Approximately 200 µl of each TREATMENT will be topically applied per test field (1.1 cm2) once daily during a 12-day treatment period (10 treatments)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Approximately 200 µl of each TREATMENT will be topically applied per test field (1.1 cm2) once daily during a 12-day treatment period (10 treatments)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daivonex® ointment
Description: Approximately 200 µl of each TREATMENT will be topically applied per test field (1.1 cm2) once daily during a 12-day treatment period (10 treatments).
Study: NCT03233594

Intervention type: OTHER
Intervention: Chiropractic Group
Description: Participants will receive approximately 8 weeks of chiropractic care.

Intervention type: OTHER
Intervention: Healthy Control Group
Description: Participants will not receive any interventions.
Study: NCT02397486

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Study: NCT03947359

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Fibroscan Touch 502 M probe
Description: Measurement of liver stiffness

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Fibroscan Touch 502 M probe
Description: Measurement of liver stiffness

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Fibroscan Touch 502 S probe
Description: Measurement of liver stiffness

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Fibroscan Touch 502 S probe
Description: Measurement of liver stiffness
Study: NCT03062098

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound imaging
Description: Ultrasound imaging during embryo transfer using a small vaginal probe.
Study: NCT03883698

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sofosbuvir
Description: Sofosbuvir is the backbone of the most of the currently used anti-HCV treatment regimens

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Sofosbuvir is the backbone of the most of the currently used anti-HCV treatment regimens

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Sofosbuvir is the backbone of the most of the currently used anti-HCV treatment regimens

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daclatasvir 60 mg
Description: Daclatasvir, in combination with sofosbuvir, is approved for the treatment of hepatitis C virus infection in absence of liver cirrhosis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir 60 mg
Description: Daclatasvir, in combination with sofosbuvir, is approved for the treatment of hepatitis C virus infection in absence of liver cirrhosis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir 60 mg
Description: Daclatasvir, in combination with sofosbuvir, is approved for the treatment of hepatitis C virus infection in absence of liver cirrhosis
Study: NCT03635840

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intra Aortic Balloon Pump
Description: Intra Aortic Balloon Pump (IABP) is a circulatory mechanical support device, placed in descending aorta, distally from left subclavian artery and proximally from renal artery. IABP works with counterpulsation concept, synchronized with heart cycle. It is indicated as supportive therapy for patients undergoing revascularization, cardiogenic shock and mechanical complication.~Balloon dilatation during dyastolic phase increasing dyastolic pressure in aorta, improving coronary vascularization and myocardial oxygen supply. In systolic phase, the balloon deflates, reducing the left ventricle afterload hence decreasing myocardial oxygen demand.
Study: NCT02143310

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EVP
Study: NCT02673554

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GIP Bolus
Description: bolus injections of synthetic human GIP (50 pmol/kg body weight) administered 30 and 120 min after commencing the hyperglycemic clamp

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GIP Clamp
Description: hyperglycemic clamp with the continuous intravenous infusion of 2 pmol.kg-1.min-1 synthetic human GIP between 30 and 180 min
Study: NCT04480567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMN 307
Description: AAV Gene Therapy Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMN 307
Description: AAV Gene Therapy Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMN 307
Description: AAV Gene Therapy Infusion
Study: NCT02673554

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test (OGTT)
Description: an oral glucose challenge (75 g)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hyperglycemic clamp
Description: a hyperglycemic clamp (capillary venous glucose concentration \~ 8.5 mmol/l)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hyperglycemic clamp
Description: a hyperglycemic clamp (capillary venous glucose concentration \~ 8.5 mmol/l)
Study: NCT01721083

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Procedure: Z-track
Description: Subject received immunization by z-track

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Procedure: Bunch
Description: Subject receives immunization by bunch method.
Study: NCT04270747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABP 938
Description: Subject will receive ABP 938 2 mg (0.05 mL) IVT injection every 4 weeks for the first 3 doses, followed by once every 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABP 938
Description: Subject will receive ABP 938 2 mg (0.05 mL) IVT injection every 4 weeks for the first 3 doses, followed by once every 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: Subject will receive aflibercept 2 mg (0.05 mL) IVT injection every 4 weeks for the first 3 doses, followed by once every 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: Subject will receive aflibercept 2 mg (0.05 mL) IVT injection every 4 weeks for the first 3 doses, followed by once every 8 weeks
Study: NCT03675412

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine tablet
Description: Each eligible participant will receive one 200 mg caffeine tablet to ingest after completing all baseline study tasks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine tablet
Description: Each eligible participant will receive one 200 mg caffeine tablet to ingest after completing all baseline study tasks.
Study: NCT02482935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally
Study: NCT03961997

Intervention type: DRUG
Group type: OTHER
Intervention: Lorlatinib 50 mg
Description: Participants will receive a single dose of lorlatinib 50 mg in Period 1. Participants will receive modafinil 400 mg daily for 19 days, and a single dose of lorlatinib 50 mg on Day 15 of Period 2.

Intervention type: DRUG
Group type: OTHER
Intervention: Lorlatinib 75 mg
Description: Participants will receive a single dose of lorlatinib 75 mg in Period 1. Participants will receive modafinil 400 mg daily for 19 days, and a single dose of lorlatinib 75 mg on Day 15 of Period 2.

Intervention type: DRUG
Group type: OTHER
Intervention: Lorlatinib 100 mg
Description: Participants will receive a single dose of lorlatinib 100 mg in Period 1. Participants will receive modafinil 400 mg daily for 19 days, and a single dose of lorlatinib 100 mg on Day 15 of Period 2.
Study: NCT03330717

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: General anesthesia
Description: Patients will undergo oncologic breast surgery on general anesthesia.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypnosis sedation
Description: Patients will undergo oncologic breast surgery on hypnosis sedation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: General anesthesia with preoperative session of hypnosis
Description: Patients will undergo surgery on general anesthesia but will have a preoperative session of hypnosis relaxation.